Beth Rogozinski Founder and CEO
Signal 2 Health

Beth Rogozinski

Beth Rogozinski is the founder and CEO of Signal 2 Health, a digital health strategy and production company located in SF. Beth is a serial entrepreneur, technology professional, and business strategist who has spent the last several years focused on digital medicine. Beth was a founding member of the internationally renowned Multimedia Studies Program at SFSU where she taught and published a book on multimedia. She then worked in hardware, software and services at such top firms as Silicon Graphics (where she helped launch the Visual Workstations
division), Macromedia (where she worked on FinalCut which was sold to Apple) and the digital agency Circle (which had a successful IPO and was
then bought by Euro RSCG). Beth has since founded games and apps companies including Signal 2 Productions, Match Factor and D2S Games.
She helped produce and publish more than 30 games and apps, including over a dozen apps for health and wellness. Beth was on the founding
team at Pear Therapeutics, where she served as Chief Product and Content Officer and helped build the product and development teams and
successfully led the design, development and commercialization of six sub-clinical products. She also led the development of Pear’s first
clinical product, reSET, and the product team submission of the De Novo 510k to the FDA. reSET was cleared by the FDA on September 14, 2017 as the first ever prescription digital therapeutic. Beth is board director or advisor to many start-ups and accelerators including monARC
Bionetworks, Oncoustics, Launchpad Digital Health, and the international groups of Hardware Massive /HardwareCon. She has consulted with health and innovation centers such as Stanford University, the Mental Health Association of Maryland and the National Mental Health Innovation Center, as well as local and international venture groups. Beth serves on the Biotechnology Innovation Organization’s educational program committee for Digital Health and chairs the Brain Health committee. She has been involved in planning and executing clinical trials of digital therapeutics, has written and published on digital medicine and tech innovations, and is a frequent speaker at technology and healthcare


Send this to a friend